Intranasal Esketamine Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Third CRTCE Clinic effectively addresses the unmet need of depression and suicide
VANCOUVER, BC, Jan. 25, 2021 /PRNewswire/ - Champignon Brands Inc. (the Company ), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), Chairman and CEO Roger McIntyre today announced the opening of a new Canadian Rapid Treatment Center of Excellence (
CRTCE) clinic in Ottawa, Ontario. This third clinic joins the Mississauga and Toronto clinics (CRTCE Clinics) in addressing the unmet need of depression and suicide through novel ketamine therapy treatment.
Over twenty clinical trials have demonstrated that ketamine and esketamine have rapid and robust antidepressant effects in patients that have failed to respond to conventional antidepressants. During the COVID-19 pandemic, the need for effective treatment has become exponentially critical, said Dr. Joshua Rosenblat, Medical Director, CRTCE. Ketamine treatment for depression is very difficult to access in Canada. This thi ....

British Columbia , Roger Mcintyre , Rogers Mcintyre , Kevin Kratiuk , Joshua Rosenblat , Pharmacology University Of Toronto , Altmed Capital Corp , Champignon Brands Inc , Canadian Rapid Treatment Center , Champignon Brands , Medical Director , Ketamine Infusions , Vice President , Brands Inc , Pharmacology University , Intravenous Ketamine Infusion Therapy , Intranasal Esketamine Therapy , Oral Ketamine Therapy , Altmed Capital , பிரிட்டிஷ் கொலம்பியா , ரோஜர் முசந்த்ிரே , ரோஜர்ஸ் முசந்த்ிரே , மருந்தியல் பல்கலைக்கழகம் ஆஃப் டொராண்டோ , கனடியன் விரைவான சிகிச்சை மையம் , மருத்துவ இயக்குனர் , கெட்டமைன் உட்செலுத்துதல் ,